C4 therapeutics reports first quarter 2022 financial results and recent business highlights

– data from ongoing cft7455 phase 1/2 trial presented at the american association for cancer research (aacr) annual meeting; enrollment continues in cohorts b1 and c –

CCCC Ratings Summary

CCCC Quant Ranking